How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,496 results for

Electronic Prescription

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

4301. Taconic Health Information Network and Community (THINC)

for drug-drug interactions. Our evaluation will measure differences in rates of medication errors and quality measures amongst these three groups. We will use a study design of a pre-post evaluation with a comparison control group. We will detect medical errors by prescription and chart review. We will determine compliance with quality measures through a combination of electronic data and chart review. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial (...) a community wide electronic data exchange. Currently, the Taconic IPA is in the midst of implementing a full electronic health record in some practices and e-prescribing in other practices. The purpose is to study the impact of an electronic health record on safety and quality measures. Condition or disease Intervention/treatment Phase Medication Errors Device: Electronic Medical Record Not Applicable Detailed Description: We propose to measure differences in patient safety and quality measures among

2005 Clinical Trials

4302. Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?

the patient's medication adherence on their index clinic visit. Initial ratings will also occur at this visit. After filling their medication prescription, all subjects will be given electronic medication caps that record each time and date their medication container is opened. Patients will then be followed in the community for the next 12 weeks to observe actual adherence to medication from the index visit to the next successive clinic visit. Every two weeks pills will be counted and data (...) will be retrieved from the electronic medication caps. During the first and last two weeks of study, blood will be sampled on two randomly selected occasions approximately 72 hours apart. Self-report and physician assessment of adherence, symptom and attitudinal measures will be obtained a second time at the second clinic visit 12 weeks after the index visit. Study Design Go to Layout table for study information Study Type : Observational Enrollment : 50 participants Allocation: Random Sample Time Perspective

2005 Clinical Trials

4303. Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years

increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with PTSD over the last 7 years Condition or disease PTSD Post-Traumatic Stress Disorder Detailed Description: This study is a retrospective electronic review of the VISN 7 Data Warehouse to determine what have been the emerging trends in prescriptions of atypical antipsychotic medications over the past seven years for the treatment of posttraumatic stress disorder (PTSD) in the VA This study is a retrospective (...) electronic review of patients of the VISN 7 Data Warehouse of patients with a diagnosis of PTSD treated with antipsychotics as monotherapy or adjunctive therapy at a VA Medical Center or VA clinic in VISN 7 (GA, SC, and AL). The data will be retrieved from a computerized list of patients treated in VA VISN 7 for PTSD from 1998-2005 and cross-referenced with the electronic pharmacy file for having received a prescription of an antipsychotic medication. No personal identifiers will be collected. The data

2005 Clinical Trials

4304. Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the electronic diary. Exclusion Criteria: Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study Erosive Esophagitis seen on endoscopy during study screening. Co-existing diseases affecting the esophagus. Abnormal laboratory values that suggest significant clinical disease. Known acquired immunodeficiency syndrome (...) . Outcome Measures Go to Primary Outcome Measures : Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median [ Time Frame: 4 weeks ] The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean [ Time Frame: 4 weeks

2005 Clinical Trials

4305. Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subjects with Non-Erosive Gastroesophageal Reflux Disease identifying their main symptom as heartburn. History of episodes of heartburn for 6 months or longer prior to screening. History of episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the electronic diary. Exclusion Criteria: Use of prescription (...) as Assessed by Daily Electronic Diary-Median [ Time Frame: 4 weeks ] The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean [ Time Frame: 4 weeks ] The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime

2005 Clinical Trials

4306. Improving Safety By Computerizing Outpatient Prescribing

The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety. No Intervention: Care as Usual In this arm, clinicians did not receive the medication safety alerts. Outcome Measures Go to Primary Outcome Measures : Preventable Adverse drug events [ Time Frame: 8/5/2004 - 1/5/2005 ] Data were electronically collected each time a physician entered a prescription that triggered an alert related to medication safety. Secondary (...) strategies such as computerization of prescribing supplemented by decision-support. Condition or disease Intervention/treatment Phase Impact of Electronic Prescribing on Medication Safety Other: Adverse Drug Event Monitoring Not Applicable Detailed Description: Specific Aim 1: Increase routine identification of outpatient adverse drug events (ADEs) through development of a computerized ADE detection monitor. Specific Aim 2: Use basic computerized outpatient prescribing to reduce preventable ADEs

2005 Clinical Trials

4307. Telephone-Based Program to Promote Inhaled Corticosteroid Adherence Among Individuals With Asthma

treatment adherence for other chronic medical conditions. This 19-month study will enroll approximately 14,000 members of the Kaiser Permanente Northwest or Hawaii health system. Participants will be randomly assigned to either take part in the telephone intervention or receive usual medical care. Over the 19-month period, participants in the intervention group will receive between one and eight phone calls that will remind them to refill their prescriptions and offer education about ICS. If needed (...) , the call may also offer a transfer to a pharmacy refill line or to speak with a pharmacist. Approximately 2,000 participants will complete questionnaires at study entry and at the end of the 19-month intervention period. The questionnaires will assess quality of life, respiratory health, asthma control, depression, inhaler use beliefs, and satisfaction with the intervention. Electronic medical record data and questionnaires will be used to determine adherence rates. Study Design Go to Layout table

2006 Clinical Trials

4308. Involving Community Pharmacies in Improving Asthma Outcomes in an Urban Pediatric Population

been shown to improve outcomes. (1) Outcomes will be assessed by blinded and structured patient phone interview at 1, 3, and 6 months. Patients randomized to usual pharmacy care will fill prescriptions by their usual preferred method, whereas patients randomized to enhanced pharmacy care will have these same prescriptions electronically transmitted to specifically trained pharmacists at one of the participating community pharmacies. Both "usual pharmacy care" and "enhanced pharmacy care (...) " will be provided within all participating pharmacy sites. Community pharmacies located in five zip codes in Northeast and Southeast DC with the highest absolute numbers of pediatric ED asthma visits to hospital in the District (20019, 20020, 20032, 20002, 20011) will be selected for the program based on their geographic distribution and ability to meet programmatic expectations. Pharmacies will receive electronically transmitted, faxed or verbal prescriptions from the IMPACT DC Asthma Clinic staff for patients

2007 Clinical Trials

4309. Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain

relief. The patient must be willing and able to successfully self-administer the study drug,comply with study restrictions, complete the electronic diary, and return to the clinic for scheduled study visits as specified in this protocol. Exclusion Criteria: The patient has uncontrolled or rapidly escalating pain as determined by the investigator (i.e., the around-the-clock (ATC) therapy may be expected to change between the first and last treatments with study drug), or has pain uncontrolled (...) . The patient has participated in a study involving an investigational drug in the prior 30 days. The patient is currently using prescription FBT or immediate-release oxycodone for BTP and is unwilling to undergo re-titration. The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug. The patient has any other medical condition or is receiving concomitant medication/therapy (eg, regional nerve block) that could, in the opinion of the investigator

2007 Clinical Trials

4310. Over-the-Counter Medication Usage

Date : November 2008 Actual Study Completion Date : February 2009 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Electronic prescription Patients receive a prescription for specific over-the-counter medications. Behavioral: Prescription Patients receive a prescription for a specific over-the-counter medication. Active Comparator: Verbal advice Behavioral: Verbal advice Patients receive verbal advice (...) : Other Study ID Numbers: 07.02.01 First Posted: February 23, 2007 Last Update Posted: November 23, 2009 Last Verified: November 2009 Keywords provided by Florida Hospital: Calcium Compliance Medication compliance electronic prescription over-the-counter medications OTC medications

2007 Clinical Trials

4311. A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia

: No Criteria Inclusion Criteria: age 18-80, meet ACR criteria for FM for more than 6 months, may or may not have a diagnosis of major depressive disorder (not bipolar) past or present, Current major depressive episode must be without psychotic features Not be on medication known to increase risk of TMS-induced seizures No prescription medication changes in the previous 4 weeks with agreement not to change during the treatment course (2 weeks) and 2 weeks thereafter No history of epilepsy or stroke (...) Increased intracranial pressure Brain surgery, or head trauma with loss of consciousness for > 15 minutes Implanted electronic device Metal in the head, or pregnant Has an active autoimmune, endocrine, viral, or vascular disorder affecting the brain or unstable cardiac disease Uncontrolled hypertension, or severe renal or liver insufficiency Unstable and active suicidal intent or plan History of attempt requiring medical hospitalization within in the past 6 months -currently an involuntary inpatient

2007 Clinical Trials

4312. Use of a Remote-Monitoring System to Diagnose and Treat Obstructive Sleep Apnea

satisfaction of this system will also be assessed. Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea. We intend to perform a randomized controlled trial of this system (...) and CPAP therapy is initiated. After prescription of CPAP, all patients will be seen by our CPAP coordinator and oriented to the device during a 20 minute session. Patients are also provided the telephone number of the CPAP coordinator who can be contacted if any problems or questions arise. Experimental: 2 Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing

2007 Clinical Trials

4313. Evaluating Ways to Improve Medication Use Among People With Osteoporosis

will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among patients. Doctors will also receive alerts about any of their participating patients who are not filling medication prescriptions. The alert message will be provided in both paper and electronic format. The electronic format can be easily formatted, allowing the doctor to send a personalized letter to their patients. At the end of the study, all (...) and Musculoskeletal and Skin Diseases (NIAMS) Information provided by (Responsible Party): Daniel H. Solomon, M.D.,MPH, Brigham and Women's Hospital Study Details Study Description Go to Brief Summary: Osteoporosis is a common bone disease in older adults in which the bones become weaker and prone to fracture. Medications are available to slow or even stop disease progression. However, very few adults who are prescribed osteoporosis medications actually follow through with filling their prescriptions and taking

2007 Clinical Trials

4314. CBT for Adherence and Depression in Diabetes

[ Time Frame: Measured at Month 4 ] Medical adherence is a percent via the electronic monitoring using glucometer. This is a percent with a possible range of 0-100, with higher scores denoting better adherence. Percent Medication Adherence Via MEMS [ Time Frame: month 4 ] This is an electronic pill cap at the acute outcome assessment. This is a percent with a possible range of 0-100, higher scores indicating greater adherence Clinician Rated Depression (MADRS) at the Acute Timepoint [ Time Frame (...) . This percentage adherence score was averaged at 4, 8, and 12 months between all participants in each arm, and those values were then averaged to give an overall percentage adherence score for each arm throughout the course of the study. Percent Medication Adherence During Follow up [ Time Frame: Aggregate across 4,8,12 months ] Electronic pill cap adherence which indicates a percentage of doses taken. This percentage of doses taken was averaged at 4, 8, and 12 months between all participants in each arm

2007 Clinical Trials

4315. Asthma Clinical Research Network (ACRN) Trial

containing a low dose of inhaled corticosteroid medication. Participants then are assigned to take part in either the BASALT study or the Tiotropium as an Alternative to Long-Acting Beta-Agonists and Corticosteroids (TALC) study, which is a separate Asthma Clinical Research Network (ACRN) study. Participants in BASALT undergo 2 to 4 weeks of adherence testing, which involves using three inhalers that have electronic monitoring devices attached to them. Participants also are asked to measure and record (...) millimeter (mg/mL) or less when not on an inhaled corticosteroid, or 16 mg/mL or less when on an inhaled corticosteroid Need for daily controller therapy (i.e., inhaled corticosteroids, leukotriene modifiers, and/or long-acting beta-agonists) based on one or more of the following criteria: Received prescription for or used asthma controller within the 12 months prior to study entry OR Experienced symptoms for more than twice a week and not on asthma controller If on inhaled steroids (any drug at any dose

2007 Clinical Trials

4316. Evaluation of Spirometry Expert Support in General Practice

in the proportion of cases in which the GP opts for the gold standard treatment (prescription, referrals) before versus after the addition of expert/sham information Study II: between-group difference in the proportion of ordered additional investigations and referrals by GPs Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn (...) more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: GP practices with a Windows supported electronic Patient Journal System (PJS) in a certain postal region in the Netherlands. Exclusion Criteria: GP practices without

2005 Clinical Trials

4317. Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III)

outcomes, but the literature is inconclusive and their cost-effectiveness is unproven. In addition, combining centralized electronic up-to-date information on the patient's status with evidence-based recommendations and the ability to communicate either electronically or by phone is expected to result in improved access to care, quality of care, continuity of care and increase cost-effectiveness of chronic disease management. COMPETE III builds on the researchers' previous work to study an electronic (...) specialists and care coordinator via an electronic network (Web, fax and telephone) sharing an intensive tracking, advice and support program, will lower their vascular risk more than those in usual care. Condition or disease Intervention/treatment Phase Vascular Diseases Behavioral: Vascular Management Program Behavioral: Clinical Care Coordinators Behavioral: Web-based Vascular Tracker for Patient and Physician Behavioral: Automated Telephone Reminder System Not Applicable Detailed Description: COMPETE

2005 Clinical Trials

4318. e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems

of 400 patients with cognitive impairment who have been hospitalized in a medical ward will be recruited for this study. Patients will be randomized to receive either standard care or the proactive screening program for CI combined with the modified CDSS. The electronic medical record for all patients will be reviewed for prescriptions for potentially inappropriate medications, urinary catheters, or physical restraints during the first 24 hours and the entire hospital stay. Medical records (...) will be used to determine the total number of hospital acquired complications that may be related to CI; these include falls, injuries such as pulling out IV lines or urinary catheters, pressure ulcers, and new-onset delirium episodes that developed during hospitalization. Also, the time elapsed between screening for CI and the physician ordering a geriatric consultation will be calculated using the electronic medical record. Study Design Go to Layout table for study information Study Type : Interventional

2005 Clinical Trials

4319. Applying Web Technology to Buprenorphine Treatment

intervention Procedure: community-based substance abuse counseling Not Applicable Detailed Description: The partial opioid agonist, buprenorphine, was recently approved by the FDA for the treatment of opioid-dependence and will be available via physician prescription, enabling a greatly needed expansion of access to opioid treatment services. However, physicians, because of considerable demands on their time, will likely be unable to provide or coordinate referral for opioid-dependent patients to receive (...) education in office-based buprenorphine treatment. During Phase II, we plan to complete our research and development efforts on this project. We will complete all educational modules of the system. We will also develop a "customization program" that patients can use to help them identify the optimal order in which they may access the program modules while in treatment. Additionally, we will establish an electronic reporting system that will provide physicians prescribing buprenorphine with patient

2005 Clinical Trials

4320. Preventing Adverse Drug Events With PatientSite

primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions. Condition or disease Intervention/treatment Phase Adverse Drug Event Other: Medcheck message Not Applicable Detailed Description: A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription (...) . In this study new enhancements will be tested. Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety. To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group

2005 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>